Greenbrook TMS Inc., together with its subsidiaries, operates a network of outpatient mental health services centers in the United States. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Greenbrook TMS's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GBOK.F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: GBOK.F underperformed the US Healthcare industry which returned 16.7% over the past year.
Return vs Market: GBOK.F underperformed the US Market which returned 12.7% over the past year.
Price Volatility Vs. Market
How volatile is Greenbrook TMS's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Greenbrook TMS undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GBOK.F ($1.05) is trading below our estimate of fair value ($8.82)
Significantly Below Fair Value: GBOK.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GBOK.F is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: GBOK.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GBOK.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GBOK.F is overvalued based on its PB Ratio (3.7x) compared to the US Healthcare industry average (2.8x).
How is Greenbrook TMS forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if GBOK.F's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if GBOK.F's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GBOK.F's revenue (43.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: GBOK.F's revenue (43.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GBOK.F's Return on Equity is forecast to be high in 3 years time
How has Greenbrook TMS performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GBOK.F is currently unprofitable.
Growing Profit Margin: GBOK.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GBOK.F is unprofitable, and losses have increased over the past 5 years at a rate of 53.1% per year.
Accelerating Growth: Unable to compare GBOK.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GBOK.F is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: GBOK.F has a negative Return on Equity (-126.35%), as it is currently unprofitable.
How is Greenbrook TMS's financial position?
Financial Position Analysis
Short Term Liabilities: GBOK.F's short term assets ($26.5M) exceed its short term liabilities ($21.3M).
Long Term Liabilities: GBOK.F's short term assets ($26.5M) exceed its long term liabilities ($24.9M).
Debt to Equity History and Analysis
Debt Level: GBOK.F's debt to equity ratio (15.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GBOK.F's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GBOK.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GBOK.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Greenbrook TMS current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GBOK.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GBOK.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GBOK.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GBOK.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GBOK.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bill Leonard (55 yo)
Mr. Bill Leonard serves as President and Chief Executive Officer of Greenbrook TMS Inc since 2011 and also serves as its Director since February 2018. Mr. Leonard is the President and Chief Executive Offic ...
CEO Compensation Analysis
Compensation vs Market: Bill's total compensation ($USD500.00K) is about average for companies of similar size in the US market ($USD601.89K).
Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.
|CFO, Treasurer & Corporate Secretary||2.58yrs||US$375.00k||no data|
|Chief Operating Officer||2.58yrs||US$307.50k||no data|
|Chief Marketing Officer||1.33yrs||US$372.60k||no data|
|Chief Medical Officer||3.67yrs||US$232.40k||no data|
|Investor Relations Officer||no data||no data||no data|
Experienced Management: GBOK.F's management team is considered experienced (2.6 years average tenure).
|Independent Director||1.25yrs||US$12.50k||no data|
|Independent Director||1.92yrs||US$25.00k||0.30% |
|Independent Director||1.92yrs||US$25.00k||no data|
|Lead Independent Director||no data||US$30.00k||0.037% |
|Independent Director||1.92yrs||US$30.00k||no data|
Experienced Board: GBOK.F's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.5%.
Greenbrook TMS Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Greenbrook TMS Inc.
- Ticker: GBOK.F
- Exchange: OTCPK
- Founded: 2011
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: CA$93.842m
- Listing Market Cap: CA$70.516m
- Shares outstanding: 67.51m
- Website: https://www.greenbrooktms.com
Number of Employees
- Greenbrook TMS Inc.
- 890 Yonge Street
- 7th Floor
- M4W 3P4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GTMS||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Oct 2018|
|GBOK.F||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Oct 2018|
Greenbrook TMS Inc., together with its subsidiaries, operates a network of outpatient mental health services centers in the United States. It offers transcranial magnetic stimulation therapy, an FDA-cleare ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/23 06:20|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.